Physician profile
Lynn T Parente
NPI 1003891110
$2,826.23
in general payments reported to CMS, 2019-2025
28 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $196 · 2021: $426 · 2022: $335 · 2023: $446 · 2024: $869 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115 · Travel and Lodging: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.09 |
| Travel and Lodging | $434.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $675.04 | 2024 | Solyx Sis System |
| Abbvie INC. | $646.07 | 2019-2025 | |
| Hologic Sales and Service, LLC | $212.70 | 2021-2023 | Aptima |
| Conmed Corporation | $169.87 | 2025 | Airseal |
| Mayne Pharma Commercial LLC | $164.67 | 2021-2024 | |
| Mylan Pharmaceuticals INC. | $122.83 | 2019-2022 | |
| Daiichi Sankyo INC. | $95.81 | 2019-2023 | Injectafer |
| Exeltis, USA INC. | $72.84 | 2019-2023 | Slynd |
| Avion Pharmaceuticals | $72.66 | 2019-2023 | Balcoltra |
| Merck Sharp & Dohme LLC | $61.12 | 2019-2021 | |
| Agile Therapeutics, INC. | $60.04 | 2021-2024 | Twirla |
| Lupin INC. | $49.99 | 2019-2020 | |
| Organon LLC | $46.46 | 2021-2025 | Nexplanon |
| Innovation Technologies INC | $44.26 | 2024 | Irrisept |
| Bayer Healthcare Pharmaceuticals INC. | $43.98 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $38.80 | 2022 | |
| Pfizer INC. | $35.73 | 2019 | |
| Sumitomo Pharma America, INC. | $35.35 | 2024-2025 | Gemtesa, Myfembree |
| Biogen, INC. | $28.40 | 2024 | |
| Coopersurgical, INC. | $21.31 | 2024 | Paragard T 380a |
| Pacira Pharmaceuticals Incorporated | $19.08 | 2025 | Exparel |
| Biohaven Pharmaceutical Holding Company LTD. | $18.02 | 2022 | |
| Duchesnay USA Incorporated | $17.57 | 2019 | |
| Covidien LP | $17.28 | 2020 | |
| Myovant Sciences INC. | $15.44 | 2021 | |
| Millicent US INC | $14.96 | 2020 | |
| Shield Therapeutics INC | $14.51 | 2024 | |
| Minerva Surgical, INC | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Parente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.